GTS Securities’s Tonix Pharmaceuticals TNXP Stock Holding History

GTS Securities’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$5.67K	–	4421
2023 Q4	$5.67K	Buy	+4	New	+$6.44K	﹤0.01%	3938

Other funds holding TNXP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GTS Securities's TNXP Position: Q1 2024 in Review

GTS Securities sold out of Tonix Pharmaceuticals (TNXP) in Q1 2024, closing a stake of 4 shares — an estimated $5.67K sold.

GTS Securities first reported a position in TNXP in Q4 2023 and held it in 1 quarter. The position peaked at $5.67K in Q4 2023. 24 funds tracked by Wall St. Rank hold TNXP as of Q1 2024.

GTS Securities reported no remaining Tonix Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
GTS Securities sold 4 Tonix Pharmaceuticals shares in Q1 2024, an estimated $5.67K.
GTS Securities first reported a position in Tonix Pharmaceuticals in Q4 2023 and held it in 1 quarter.
GTS Securities's Tonix Pharmaceuticals position peaked at $5.67K in Q4 2023.
24 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.